Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$100.19 USD
-4.11 (-3.94%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $100.09 -0.10 (-0.10%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$100.19 USD
-4.11 (-3.94%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $100.09 -0.10 (-0.10%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Ligand (LGND) Down 14% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ligand (LGND) Q1 Earnings Top, Bad Weather Hits Captisol Sales
by Zacks Equity Research
Ligand (LGND) reports mixed first-quarter 2021 numbers with earnings beating estimates but revenues missing the same. Stock down.
Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates
by Zacks Equity Research
Ligand (LGND) delivered earnings and revenue surprises of 34.29% and -15.61%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Central Banks Start to Care About Fundamentals?
by John Blank
Macro-data has been much stronger than expected.¿¿¿¿¿¿ Still, the only thing that matters is NOT whether stock traders (or pundits) take note of strong data. It is whether the Fed and other major central banks care.
Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Ligand (LGND) Down 21.3% Since Last Earnings Report?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ligand (LGND) Q4 Earnings & Sales Top, 2021 Guidance Raised
by Zacks Equity Research
Ligand (LGND) reports better-than-expected fourth-quarter 2020 numbers. The company raises outlook for 2021.
WallStreetBets: The Big Short-Squeeze
by Daniel Laboe
Will WallStreetBets mark the end of short-selling as we know it, or was GME a one-time sideshow in the market?
Biotech Stock Roundup: PFE/BNTX Vaccine Authorized in Europe, Updates From AMGN, & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) continue to take centerstage in the biotech sector.
Ligand (LGND) Up 3.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ligand (LGND) Q3 Earnings & Sales Fall Short of Estimates
by Zacks Equity Research
Ligand (LGND) reports lower-than-expected third-quarter 2020 earnings and revenues. Outlook for 2020 & 2021 also are below expectations. Stock down.
Ligand Pharmaceuticals (LGND) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Ligand (LGND) delivered earnings and revenue surprises of -1.89% and -8.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Higher Captisol sales to support availability of Gilead's COVID-19 treatment, remdisivir, is expected to have driven Ligand's (LGND) revenues in the third quarter.
Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol Myers to Buy MyoKardia to Aid Cardiovascular Franchise
by Zacks Equity Research
Bristol Myers (BMY) offers $13.1 billion to acquire MyoKardia for diversifying its cardiovascular product portfolio. The transaction is expected to close in the fourth quarter of 2020.
AMAG (AMAG) to be Acquired by Covis Group for $647 Million
by Zacks Equity Research
AMAG (AMAG) is set to be acquired by Covis Group for approximately $647 million.
bluebird's MAA for Elivaldogene Autotemcel Accepted by EMA
by Zacks Equity Research
bluebird's (BLUE) MAA for elivaldogene autotemcel gene therapy for the treatment of patients with cerebral adrenoleukodystrophy is accepted by the the European Medicines Agency.
ADMA Biologics (ADMA) Surges: Stock Moves 8.6% Higher
by Zacks Equity Research
ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
LGND or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. ALKS: Which Stock Is the Better Value Option?
Ligand Pharmaceuticals Enters Oversold Territory
by Zacks Equity Research
Ligand Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
LGND or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. ALKS: Which Stock Is the Better Value Option?
Ligand (LGND) Down 13.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
LGND vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
LGND vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
Ligand (LGND) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Ligand (LGND) reports better-than-expected second-quarter 2020 earnings and revenues. Stock up.